Holen Sie sich die Stockscreener-App
6.90
4.56%
-0.33
Handel nachbörslich:
6.89
-0.01
-0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.23
Offen:
$7.36
24-Stunden-Volumen:
1.42M
Relative Volume:
1.10
Marktkapitalisierung:
$679.05M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-174.33M
KGV:
-3.4126
EPS:
-2.0219
Netto-Cashflow:
$-157.44M
1W Leistung:
-7.38%
1M Leistung:
-7.88%
6M Leistung:
+75.57%
1J Leistung:
+63.12%
1-Tages-Spanne:
$6.7616
$7.48
1-Wochen-Bereich:
$6.7616
$7.535
52-Wochen-Spanne:
$2.41
$8.8661
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.90 | 711.53M | 14.79M | -174.33M | -157.44M | -2.0219 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Guggenheim | Buy |
| 2025-12-04 | Eingeleitet | Needham | Buy |
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Invus and affiliates hold 9.99% of Solid Biosciences (NASDAQ: SLDB) via warrants and shares - Stock Titan
One new Solid Biosciences employee gets 8,070 stock units - Stock Titan
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy - marketscreener.com
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Solid Biosciences receives EU orphan drug status for SGT-003 - Investing.com UK
Solid Biosciences (SLDB) Receives Orphan Drug Designation for SG - GuruFocus
Solid Biosciences receives EU orphan drug status for SGT-003 By Investing.com - Investing.com South Africa
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
EU grants orphan status to Solid’s Duchenne gene therapy candidate - Stock Titan
Solid Biosciences Announces Receipt of European Commission - GlobeNewswire
Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist Financial - MarketBeat
BlackRock (NASDAQ: SLDB) holds 4.7% of Solid Biosciences, 4.58M shares - Stock Titan
Solid Biosciences Inc. sponsors SADS Foundation symposium to back genetic heart rhythm research - Traders Union
Solid Biosciences announces $240 million private placement - MSN
Solid Biosciences Inc. commits to industry and advocacy collaboration on Duchenne - Traders Union
Solid Biosciences (NASDAQ: SLDB) seeks approval to double authorized shares at 2026 meeting - Stock Titan
Solid Biosciences (SLDB) COO earns 79,341 RSUs on performance milestone - Stock Titan
Solid Biosciences (NASDAQ: SLDB) CMO awarded 58,847 RSUs on milestone - Stock Titan
Solid Biosciences (SLDB) CEO earns 169,401 RSUs tied to PSUs - Stock Titan
Solid Biosciences (SLDB) CTO earns 54,925 RSUs on performance milestone - Stock Titan
Solid Biosciences (SLDB) CFO awarded 56,647 RSUs after performance milestone - Stock Titan
Solid Biosciences (NASDAQ: SLDB) awards 54,925 performance-based RSUs - Stock Titan
Piper Sandler Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences Inc. advances SGT-212 gene therapy for Friedreich ataxia into human trials - Traders Union
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Solid Biosciences Inc. to present new targeting strategies in gene therapy - Traders Union
Solid Biosciences (NASDAQ:SLDB) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Who Backs Solid Biosciences (SLDB) Stock (Modest Uptick) 2026-04-18Index Investing - Cổng thông tin điện tử Tỉnh Sơn La
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB) - The Globe and Mail
Needham Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Solid Biosciences (NASDAQ:SLDB) Sets New 12-Month HighHere's What Happened - MarketBeat
SLDB: Guggenheim Initiates Coverage with a 'Buy' Rating at $26 | - GuruFocus
Dow Update: Is Solid Biosciences Inc part of any ETF2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9%Here's Why - MarketBeat
Sell Signal: Can Solid Biosciences Inc maintain its current growth rate2026 Short Interest & Fast Moving Trade Plans - baoquankhu1.vn
Solid Biosciences reclassifies board member Ilan Ganot to Class I director - Investing.com Australia
Solid Biosciences Inc. Files Form 8-K with SEC Detailing Company Information and No Amendments as of April 10, 2026 - Minichart
Solid Biosciences (NASDAQ:SLDB) Raised to "Hold" at Wall Street Zen - MarketBeat
Solid Biosciences reclassifies board member Ilan Ganot to Class I director By Investing.com - Investing.com Australia
Solid Biosciences Adjusts Board Classes in Governance Move - TipRanks
Solid Biosciences (NASDAQ: SLDB) asks shareholders to double authorized shares to 480,000,000 - Stock Titan
Board reshuffle at Solid Biosciences (NASDAQ: SLDB) balances director classes - Stock Titan
Activity Recap: Can Solid Biosciences Inc maintain its current growth rateOil Prices & Long-Term Safe Return Strategies - baoquankhu1.vn
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):